AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.04 USD
-0.38 (-5.92%)
Updated May 17, 2024 04:00 PM ET
After-Market: $6.05 +0.01 (0.17%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.04 USD
-0.38 (-5.92%)
Updated May 17, 2024 04:00 PM ET
After-Market: $6.05 +0.01 (0.17%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth D Momentum D VGM
Zacks News
AngioDynamics (ANGO) Q1 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
by Zacks Equity Research
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
New Strong Sell Stocks for September 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Why Is AngioDynamics (ANGO) Up 5.02% Since Its Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
Bear of the Day: AngioDynamics (ANGO)
by Kevin Cook
Small cap force in non-surgical alternatives for peripheral vascular disease hits a growth/valuation peak
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
by Zacks Equity Research
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.
AngioDynamics (ANGO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -4.76% and -0.75%, respectively, for the quarter ended May 2018. Do the numbers hold clues to what lies ahead for the stock?
Q2 Earnings Season In Focus
by Zacks Equity Research
Q2 Earnings Season In Focus
What's Sparking Market Futures? Big Q2 Results
by Mark Vickery
There is a bright, shining beacon markets appear to be attracted to currently: Q2 earnings season.
What's in Store for AngioDynamics (ANGO) in Q4 Earnings?
by Zacks Equity Research
AngioDynamics' (ANGO) expanding product pipeline, international market expansion and cost-saving initiatives to provide growth opportunities in Q4.
Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Product Line Strong, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.
AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View
by Zacks Equity Research
AngioDynamics (ANGO) witnesses gross margin expansion and strong profits in the third quarter of fiscal 2018. However, lower sales in the company's RFA product line in Japan is a concern.
AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer
by Zacks Equity Research
AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
by Zacks Equity Research
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
Bet on These 5 PEG-Ratio Based GARP Picks
by Zacks Equity Research
A lower PEG ratio, preferably less than one, is always better for GARP investors.
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
by Zacks Equity Research
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.